All articles tagged with #alnylam
At the European Society of Cardiology Congress in Munich, Alnylam's ATTR-CM therapies face new headwinds as data from rival drug eplontersen suggest it failed to significantly reduce cardiovascular deaths or recurrent events, potentially reshaping expectations for Alnylam and informing investors and clinicians about the competitive landscape.
City Therapeutics, a next-gen RNAi startup led by former Alnylam executives, has raised about $99.5 million to fund the clinical development and data collection for its first three RNAi medicines.
Alnylam Pharmaceuticals signed its first AI-driven discovery deal, paying a $30 million upfront to AI startup Inceptive to accelerate RNA research and development.
Roche's $3 billion deal with Alnylam for the rights to a hypertension treatment demonstrates a renewed interest from large pharmaceutical companies in developing long-acting heart drugs, as the cardiovascular disease market has been overshadowed by cancer and other diseases.